Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number
of clinical features and pathogenic mechanisms with idiopathic pulmonary fibrosis (IPF). This …

To assess the efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung
disease (SSc-ILD). This was a double-blind, randomised, placebo-controlled, pilot study …

Background Interstitial lung disease is a known complication of rheumatoid arthritis, with a
lifetime risk of developing the disease in any individual of 7· 7%. We aimed to assess the …

Background Pirfenidone has been shown to slow disease progression in patients with
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …

Background: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in
patients with systemic sclerosis (SSc). To date, clinical practice guidelines regarding …

Background and objective Pirfenidone is an oral antifibrotic agent that is approved in several
countries for the treatment of idiopathic pulmonary fibrosis (IPF). We performed a …

Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …

Interstitial lung disease (ILD) is a common manifestation of systemic autoimmune diseases
and a leading cause of death in these patients. A proportion of patients with autoimmune …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …